Roche claims midstage win for obesity injectable Roche reports weight loss of up to 22.5% with its injectable GIP/GLP-1 agonist obesity drug, setting up phase 3, but will it be too late to the table?

#weightloss #obesity #drugdevelopment #Roche #obesityinjectable #phase2results #dualGIPGLP1agonist #phase3programme #CT388 #CarmotTherapeutics #BMI #GLP1directedmedicines #EliLilly #GIPGLP1activity #NovoNordisk #GLP1drug #obesitycategory #IQVIA #ZealandPharma
zurl.co/nATCt

Pharma giants vie for oral GLP-1R approval - PharmaTimes Race to create first oral drug for obesity intensifies

#oralGLP1R #obesity #phase3trials #oralGLP1Rproducts #NovoNordisk #EliLilly #GLP1Rportfolios #obesitycategory #Wegovy #Saxenda #Zepbound #obesitymedication #obesityinjectables #Rybelsus #orforgliproncalcium #obesitylabelexpansion #obesitymarket #obesitylandscape
pharmatimes.com/news/pharma-...